The efficacy and tolerability of natalizumab in patients with relapsing-remitting multiple sclerosis registered via the IMed database system from 2010 in Hungary

Trial Profile

The efficacy and tolerability of natalizumab in patients with relapsing-remitting multiple sclerosis registered via the IMed database system from 2010 in Hungary

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 May 2014

At a glance

  • Drugs Natalizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 22 May 2014 New trial record
    • 03 May 2014 Results presented at the 66th Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top